Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) announced today that it has priced an underwritten public offering of 5,200,000 shares of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE